Table 2 Follow-up periods and clinical outcomes post-intravitreal gentamicin injections
Minimum follow-up period | Controlled ERU (no recurrent or persistent inflammation, independent of complications) | Average follow-up period (days) | Standard deviation (± days) | Range (days) |
|---|---|---|---|---|
30 days 59/86 (68.6%) eyes | 52/59 eyes 88.1% | 238 | 190 | 30–780 |
3 month 43/86 (50.0%) eyes | 36/43 eyes 83.7% | 313 | 175 | 93–780 |
5 month 34/86 (39.5%) eyes | 27/34 eyes 79.4% | 359 | 164 | 153–780 |
7 month 24/86 (27.9%) eyes | 20/24 83.3% | 407 | 170 | 213–780 |
1 year 12/86 (14.0%) eyes | 9/12 eyes 75% | 541 | 137 | 365–780 |